All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Methylphenidate
Therapeutic Area: Psychiatry/Psychology Product Name: Concerta
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Janssen Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 29, 2020
Details:
The strong and diverse portfolio includes: CONCERTA®, HALDOL®, HALDOL® DECANOAS, REMINYL®, SIBELIUM®, RISPERDAL®, RISPERDAL CONSTA® and TOPAMAX®.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Aripiprazole
Therapeutic Area: Psychiatry/Psychology Product Name: Abilify Maintena
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2020
Details:
Otsuka Pharmaceutical created ABILFY MAINTENA, an atypical antipsychotic, which first received regulatory approval in 2013 in the U.S. and E.U. for the treatment of adult schizophrenia.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Buprenorphine
Therapeutic Area: Psychiatry/Psychology Product Name: Sixmo
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Molteni Farmaceutici
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 14, 2020
Details:
Under the terms of the agreement, Accord will commercialize Sixmo®▼ (buprenorphine implant), an opioid agonist therapy treatment, delivered through a first-of-its-kind implant, placed under the skin for six-months.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Quetiapine Fumarate
Therapeutic Area: Psychiatry/Psychology Product Name: Seroquel
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: CAP ALTER PHARMA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 11, 2020
Details:
Luye Pharma granted exclusive promotional rights to CAP ALTER PHARMA, INC (Alter-Pharma) for Seroquel products in 9 countries and regions including Costa Rica, Jamaica, Trinidad and Tobago, Barbados, Aruba, Curacao, Bahamas, Bermuda and The Cayman Islands.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Naloxone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Narcan
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 17, 2020
Details:
Narcan Nasal Spray was the first intranasal form of naloxone approved by FDA and Health Canada for the emergency treatment of known or suspected opioid overdose.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Olanzapine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 06, 2020
Details:
Olanzapine is indicated for the treatment of schizophrenia and bipolar disorder. The drug may also be used in combination with other medication to treat depression and certain mental conditions.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Methylphenidate Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Quillivant XR
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: KYE Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 09, 2020
Details:
Under the terms of the agreement, KYE has received exclusive rights to commercialize Tris' FDA-approved ADHD product portfolio in Canada. Also, KYE will handle all ongoing Canadian regulatory activities for the products.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Buprenorphine
Therapeutic Area: Psychiatry/Psychology Product Name: Probuphine
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Indegene Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 24, 2020
Details:
The partnership will establish multichannel digital marketing programs throughout the United States and expand the capabilities for the engagement of health care providers ("HCPs") who are eligible to prescribe Titan's Probuphine® (buprenorphine) implant.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Clozapine
Therapeutic Area: Psychiatry/Psychology Product Name: Versacloz
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Tasmanian Alkaloids Pty Ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 22, 2020
Details:
Tanner to distribute Versacloz in areas outside of the U.S where the product is not yet registered. Versacloz is indicated for the treatment of severely ill patients with schizophrenia who fail to respond to standard antipsychotic treatment.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Methylphenidate Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Jornay PM
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2020
Details:
The data presented in the poster may help guide clinicians to target an appropriate dose range of JORNAY PM extended-release capsules CII, which was approved in August 2018 by the U.S. FDA for the treatment of ADHD in patients 6 years and older.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
